Genentech's Columvi Improves Survival Rates In Two-Year Cancer Study
23/5 07:19
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced two-year follow-up data from the Phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi (glofitamab-gxbm) in c...